2022 Ljubljana, Slovenia

II-01 Bram Agema
Improving the tolerability of osimertinib by identifying its toxic limit
Wednesday 15:10-16:40
II-02 Doaa Ahmed Mohamed
Development of a physiologically based pharmacokinetic model for intratumoral biodistribution of magnetic iron oxide nanoparticles
Wednesday 15:10-16:40
II-06 Claire Brillac
Selection of isatuximab dosing regimen in pediatric patients with leukemia using population PK and PBPK modeling approaches
Wednesday 15:10-16:40
II-07 René Bruno
Comparison of two-stage and joint TGI-OS modelling using data from six clinical studies in metastatic non-small cell lung cancer patients
Wednesday 15:10-16:40
II-08 Aurore CARROT
A joint K-PD model with the tumor size changes and CA-125 kinetics in patients with advanced ovarian cancer (AOC): analysis of the phase II BOLD study.
Wednesday 15:10-16:40
II-09 Marc Cerou
Semi-mechanistic pharmacokinetic-pharmacodynamic modeling of tumor size dynamics in advanced breast cancer patients treated with single-agent amcenestrant
Wednesday 15:10-16:40
II-11 S. Y. Amy Cheung
Exposure-Response Analysis of Tovorafenib (DAY101) Relating Objective Response to Exposure, Patient- and Disease Characteristics
Wednesday 15:10-16:40
II-13 Christian Hove Claussen
Modeling Mouse Xenograft Tumor Growth Inhibition to Optimize Cycles in Oncology
Wednesday 15:10-16:40
II-14 David Damoiseaux
Physiologically based pharmacokinetic model to predict chemotherapy exposure in infants through breastfeeding: paclitaxel as an example
Wednesday 15:10-16:40
II-15 Liu Dan
Population pharmacokinetics of selpercatinib in patients with an advanced solid tumor, including RET fusion-positive NSCLC, RET-mutant MTC, and other tumors with increased RET activity
Wednesday 15:10-16:40
II-16 Lekshmi Dharmarajan
Preclinical pharmacokinetics and target occupancy of JDQ443, a covalent inhibitor targeting KRAS G12C
Wednesday 15:10-16:40
II-18 Yin Edwards
Exposure-safety analysis of Tovorafenib (DAY101), an investigational oral pan-RAF kinase inhibitor, in oncology patients with solid tumors
Wednesday 15:10-16:40
II-23 Ana-Marija Grisic
Model-informed noninferiority of cetuximab biweekly to weekly dosing regimen in metastatic colorectal cancer
Wednesday 15:10-16:40
II-27 Heeyoon Jung
rhIL-7-hyFc dose optimization for chemotherapy-induced lymphopenia using FcRn mediated IgG disposition model
Wednesday 15:10-16:40
II-31 Marie Lambert
A population approach to compare the impact of two amino acid solutions on 177Lu-Dotatate pharmacokinetics in patients with gastroenteropancreatic neuroendocrine tumors
Wednesday 15:10-16:40
II-32 Félicien Le Louedec
Non-linear mixed-effects modeling to evaluate the pre-analytical stability of uracilemia in the context of dihydropyrimidine dehydrogenase deficiency testing.
Wednesday 15:10-16:40
II-33 Xia Li
Population Pharmacokinetics and Exposure–Response Analyses of Daratumumab in Combination With Pomalidomide and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Wednesday 15:10-16:40
II-34 Yu-wei Lin
Utilizing model informed drug development to support study design for Tovorafenib (DAY101), a novel, type II, pan RAF kinase inhibitor: a focus on longitudinal safety markers
Wednesday 15:10-16:40
II-35 Han Liu
Learning dose-response relationship via PK-TS-multistate clinical endpoints modeling framework: application to bintrafusp alfa in second-line non-small cell lung cancer patients
Wednesday 15:10-16:40
II-36 Rubin Lubomirov
Population pharmacokinetic-based, two-stage approach to assess the impact of genetic variants on lurbinectedin exposure in patients with advanced cancer
Wednesday 15:10-16:40
II-37 Corinna Maier
Semi-Mechanistic Model to Aid Clinical Understanding of Myelodysplastic Syndromes
Wednesday 15:10-16:40
II-38 Yomna Nassar
Cachexia-associated anticancer drug toxicity is minimally mediated by alteration of drug’s pharmacokinetics: Erlotinib as case study
Wednesday 15:10-16:40
II-39 Janine Nijhuis
The comparison of pharmacoeconomic and pharmacometric modelling to improve cost-effectiveness assessment of sunitinib in GIST.
Wednesday 15:10-16:40
II-40 Qing Xi Ooi
Rituximab PK and PD evaluation based on a study in diffuse large B-cell lymphoma: influence of tumor size on PK and assessment of PK similarity
Wednesday 15:10-16:40
II-41 Antoine Pitoy
Joint modeling of longitudinal and time-to-event data for earlier estimation of the primary endpoint in oncology clinical trials: A retrospective analysis of the ICARIA-MM clinical trial
Wednesday 15:10-16:40
II-42 Clémence Pouzin
Modelling approaches to support tusamitamab ravtansine (DM4 anti-CEACAM5 antibody-drug conjugate) drug development.
Wednesday 15:10-16:40
II-44 Bhaskar Rege
Use of Quantitative System Pharmacology (QSP) Modeling to Optimize Dosing Frequency and Interval for Nemvaleukin Alfa (Nemvaleukin), an Investigational Cancer Immunotherapy
Wednesday 15:10-16:40
II-45 Elisabeth Rouits
Exposure-response of different dosing schedules of naratuximab emtansine in combination with rituximab in Non Hodgkin’s lymphoma
Wednesday 15:10-16:40
II-46 Javier Sanchez Fernandez
Preclinical in vivo data integrated in a modeling network informs a refined clinical strategy for a CD3 T-Cell bispecific in combination with anti-PD-L1
Wednesday 15:10-16:40
II-47 Aymara Sancho
Characterizing the interplay between biological factors and cell growth in unperturbed tumor growth dynamics
Wednesday 15:10-16:40
II-48 Celine Sarr
A framework for prediction of progression free survival based on modelling of sub-endpoints
Wednesday 15:10-16:40
II-51 Stephan Schaller
A PB-QSP platform model for T cell-dependent bispecific antibodies
Wednesday 15:10-16:40
II-53 Hinke Siebinga
A Population Pharmacokinetic Model Using Imaging Data to Assess Variability in Pharmacokinetics of 177Lu-PSMA-617 in Low Volume Metastatic Prostate Cancer Patients
Wednesday 15:10-16:40
II-54 Zhiyuan Tan
Population Pharmacokinetics of cabozantinib in adult metastatic renal cell carcinoma patients: evaluation of real-world data
Wednesday 15:10-16:40
II-55 David Ternant
Influence of immunization on the pharmacokinetics of monoclonal antibodies : anti-drug antibody-mediated drug disposition (ADAMDD) of rituximab in mice
Wednesday 15:10-16:40
II-57 Elena Tosca
A clinical trial simulator to predict the effect of an adaptive dosing regimen of an investigated compound on platelets, white blood cells and haematocrit in patients with Polycythemia Vera.
Wednesday 15:10-16:40
II-59 Maarten Van Eijk
Optimizing the value of preclinical data for the design of first-in-human clinical studies with oral cabazitaxel through population pharmacokinetic modelling
Wednesday 15:10-16:40
II-63 Anyue Yin
Quantitative modelling of exposure-tumor dynamics relationship and development of drug resistance in non-small cell lung cancer patients treated with erlotinib
Wednesday 15:10-16:40